Alcidion Group is proud to announce the appointment of Professor Andrew Way as a non-executive board director. Professor Way previously served as the chief executive of Alfred Health from 2009 to 2024 and has held several senior positions in the England National Health Service (NHS).
Professor Way led the development of Monash Partners, Victoria’s first Academic Health Science Centre and was appointed as an adjunct clinical professor in the School of Public Health and Preventative Medicine, Faculty of Medicine Nursing and Health Sciences, Monash University in 2015. In addition to his senior leadership roles, Professor Way holds several non-executive and advisory roles both in Australia and internationally – including chair of the Department of Health’s HSV (Health Services Victoria) board.
Professor Way adds considerable value to our board, contributing expertise in quality and safety in patient care; the development of academic medical organisations; management of complex healthcare systems; and using IT as a clinical enabler. He also brings strong customer insights to the board, as Alfred Health is a long-standing customer of Alcidion.
Alcidion chair Rebecca Wilson said she was pleased to welcome Professor Way to the board.
“He brings deep sector knowledge and skills that are strongly aligned to Alcidion’s core purpose in supporting the healthcare industry and will be a great asset to the company as we continue to execute on our strategic plan. Andrew is the company’s second new director appointment, after we welcomed Will Smart last year, bringing deep international operational healthcare experience at a time when we embark on the next phase of scaling the Company and expanding our customer base.”
Professor Way will fill the board position of Victoria Weekes, who will be stepping down mid-year. Ms Weekes had served on the board for more than three years, and Alcidion gratefully acknowledges her contribution to enhancing the governance framework in alignment with Alcidion’s maturing operations. Ms Weekes’ leadership on the board and in her capacity as the chair of the audit and risk committee had provided significant positive impact, as the size and complexity of Alcidion’s customers have evolved.
New AI-powered tool aims to reduce NZ’s highrate of prescribing errors
